english.prescrire.org > Spotlight > Archives : 2026 > Enfortumab vedotin (Padcev°) + pembrolizumab (Keytruda°) in unresectable or metastatic urothelial carcinoma

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

Enfortumab vedotin (Padcev°) + pembrolizumab (Keytruda°) in unresectable or metastatic urothelial carcinoma

 Marketing Authorisations  Enfortumab vedotin, a cytotoxic drug conjugated to an anti-nectin-4 monoclonal antibody, was already authorised for use as third-line treatment in locally advanced or metastatic urothelial cancer. It is now also authorised in first-line treatment in combination with pembrolizumab. 
Full article available for download by subscribers

EDITORS' OPINION
Cutting corners

If we make several changes to a recipe at the same time (say by adding or removing ingredients, or modifying the cooking time or method), how can we know which changes influenced the final result? Making one change at a time instead would probably give us a better, clearer understanding of what we are doing, and allow us to reproduce successful outcomes...

Full text available for download by subscribers

 ©Prescrire 1 February 2026

Source: "Enfortumab vedotin (Padcev°) + pembrolizumab (Keytruda°) in unresectable or metastatic urothelial carcinoma" Prescrire Int 2026; 35 (278): 41-42. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook  
 
 
See also:
 
"Enfortumab vedotin (Padcev°)
as third, or subsequent,
treatment line for urothelial
carcinoma. An option, while
taking into account its serious
and sometimes fatal harms"
Prescrire Int 2023;
32 (252): 235-237.
Subscribers only